|
1
|
Wang J, Hu K, Cai X, Yang B, He Q, Wang J
and Weng Q: Targeting PI3K/AKT signaling for treatment of
idiopathic pulmonary fibrosis. Acta Pharm Sin B. 12:18–32.
2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Yanagihara T, Sato S, Upagupta C and Kolb
M: What have we learned from basic science studies on idiopathic
pulmonary fibrosis? Eur Respir Rev. 28(190029)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Otoupalova E, Smith S, Cheng G and
Thannickal VJ: Oxidative stress in pulmonary fibrosis. Compr
Physiol. 10:509–547. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Richeldi L, Collard HR and Jones MG:
Idiopathic pulmonary fibrosis. Lancet. 389:1941–1952.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Somogyi V, Chaudhuri N, Torrisi SE, Kahn
N, Müller V and Kreuter M: The therapy of idiopathic pulmonary
fibrosis: What is next? Eur Respir Rev. 28(190021)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kropski JA and Blackwell TS: Progress in
understanding and treating idiopathic pulmonary fibrosis. Annu Rev
Med. 70:211–224. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tepede A and Yogaratnam D: Nintedanib for
idiopathic pulmonary fibrosis. J Pharm Pract. 32:199–206.
2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
George PM, Patterson CM, Reed AK and
Thillai M: Lung transplantation for idiopathic pulmonary fibrosis.
Lancet Respir Med. 7:271–282. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chambers DC, Cherikh WS, Harhay MO, Hayes
D Jr, Hsich E, Khush KK, Meiser B, Potena L, Rossano JW, Toll AE,
et al: The international thoracic organ transplant registry of the
international society for heart and lung transplantation:
Thirty-sixth adult lung and heart-lung transplantation Report-2019;
Focus theme: Donor and recipient size match. J Heart Lung
Transplant. 38:1042–1055. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fattman CL: Apoptosis in pulmonary
fibrosis: Too much or not enough? Antioxid Redox Signal.
10:379–385. 2008.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Olajuyin AM, Zhang X and Ji HL: Alveolar
type 2 progenitor cells for lung injury repair. Cell Death Discov.
5(63)2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Corrin B, Dewar A, Rodriguez-Roisin R and
Turner-Warwick M: Fine structural changes in cryptogenic fibrosing
alveolitis and asbestosis. J Pathol. 147:107–119. 1985.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Myers JL and Katzenstein AL: Epithelial
necrosis and alveolar collapse in the pathogenesis of usual
interstitial pneumonia. Chest. 94:1309–1311. 1988.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li XP, Shu RJ, Filippatos G and Uhal BD:
Apoptosis in lung injury and remodeling. J Appl Physiol (1985).
97:1535–1542. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Uhal BD, Joshi I, Hughes WF, Ramos C,
Pardo A and Selman M: Alveolar epithelial cell death adjacent to
underlying myofibroblasts in advanced fibrotic human lung. Am J
Physiol. 275:L1192–L1199. 1998.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Barbas-Filho JV, Ferreira MA, Sesso A,
Kairalla RA, Carvalho CR and Capelozzi VL: Evidence of type II
pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary
fibrosis (IFP)/usual interstitial pneumonia (UIP). J Clin Pathol.
54:132–138. 2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chen F, Gong L, Zhang L, Wang H, Qi X, Wu
X, Xiao Y, Cai Y, Liu L, Li X and Ren J: Short courses of low dose
dexamethasone delay bleomycin-induced lung fibrosis in rats. Eur J
Pharmacol. 536:287–295. 2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Bock FJ and Tait SWG: Mitochondria as
multifaceted regulators of cell death. Nat Rev Mol Cell Biol.
21:85–100. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Budinger GR, Mutlu GM, Eisenbart J, Fuller
AC, Bellmeyer AA, Baker CM, Wilson M, Ridge K, Barrett TA, Lee VY
and Chandel NS: Proapoptotic Bid is required for pulmonary
fibrosis. Proc Natl Acad Sci USA. 103:4604–4609. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hu X, Xu Q, Wan H, Hu Y, Xing S, Yang H,
Gao Y and He Z: PI3K-AKT-mTOR/PFKFB3 pathway mediated lung
fibroblast aerobic glycolysis and collagen synthesis in
lipopolysaccharide-induced pulmonary fibrosis. Lab Invest.
100:801–811. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Zhao H, Li C, Li L, Liu J, Gao Y, Mu K,
Chen D, Lu A, Ren Y and Li Z: Baicalin alleviates bleomycin-induced
pulmonary fibrosis and fibroblast proliferation in rats via the
PI3K/AKT signaling pathway. Mol Med Rep. 21:2321–2334.
2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Schmitt-Ney M: The FOXO's advantages of
being a family: Considerations on function and evolution. Cells.
9(787)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li H, Kan B, Song L, Liu Y and Jian X:
Role of the Hippo signaling pathway in safflower yellow pigment
treatment of paraquat-induced pulmonary fibrosis. J Int Med Res.
48(300060520905425)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Takano M, Deguchi J, Senoo S, Izumi M,
Kawami M and Yumoto R: Suppressive effect of quercetin against
bleomycin-induced epithelial-mesenchymal transition in alveolar
epithelial cells. Drug Metab Pharmacokinet. 35:522–526.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sun X, Cui X, Chen X and Jiang X:
Baicalein alleviated TGF β1-induced type I collagen production in
lung fibroblasts via downregulation of connective tissue growth
factor. Biomed Pharmacother. 131(110744)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhou Y, Zhu WP, Cai XJ and Chen M:
Atomized paclitaxel liposome inhalation treatment of
bleomycin-induced pulmonary fibrosis in rats. Genet Mol Res.
15(10)2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hu Y, Li M, Zhang M and Jin Y: Inhalation
treatment of idiopathic pulmonary fibrosis with curcumin large
porous microparticles. Int J Pharm. 551:212–222. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhang YY, Yi M and Huang YP: Oxymatrine
ameliorates doxorubicin-induced cardiotoxicity in rats. Cell
Physiol Biochem. 43:626–635. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Xiang X, Tu C, Li Q, Wang W, Huang X, Zhao
Z, Xiong H and Mei Z: Oxymatrine ameliorates imiquimod-induced
psoriasis pruritus and inflammation through inhibiting heat shock
protein 90 and heat shock protein 60 expression in keratinocytes.
Toxicol Appl Pharmacol. 405(115209)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang D, Lou XQ, Jiang XM, Yang C, Liu XL
and Zhang N: Oxymatrine protects against the effects of
cardiopulmonary resuscitation via modulation of the TGF-β1/Smad3
signaling pathway. Mol Med Rep. 17:4747–4752. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ying XJ, Jin B, Chen XW, Xie J, Xu HM and
Dong P: Oxymatrine downregulates HPV16E7 expression and inhibits
cell proliferation in laryngeal squamous cell carcinoma Hep-2 cells
in vitro. Biomed Res Int. 2015(150390)2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Liu Y, Xu Y, Ji W, Li X, Sun B, Gao Q and
Su C: Anti-tumor activities of matrine and oxymatrine: Literature
review. Tumour Biol. 35:5111–5119. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Song WJ, Luo J, Wu T and Yao SK: Oral
oxymatrine preparation for chronic hepatitis B: A systematic review
of randomized controlled trials. Chin J Integr Med. 22:141–149.
2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shi HJ, Zhou H, Ma AL, Wang L, Gao Q,
Zhang N, Song HB, Bo KP and Ma W: Oxymatrine therapy inhibited
epidermal cell proliferation and apoptosis in severe plaque
psoriasis. Br J Dermatol. 181:1028–1037. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Huang Y, Li X, Zhang X and Tang J:
Oxymatrine ameliorates memory impairment in diabetic rats by
regulating oxidative stress and apoptosis: Involvement of
NOX2/NOX4. Oxid Med Cell Longev. 2020(3912173)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chen Q, Duan X, Fan H, Xu M, Tang Q, Zhang
L, Shou Z, Liu X, Zuo D, Yang J, et al: Oxymatrine protects against
DSS-induced colitis via inhibiting the PI3K/AKT signaling pathway.
Int Immunopharmacol. 53:149–157. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Liu Y, Wang H, Liu N, Du J, Lan X, Qi X,
Zhuang C, Sun T, Li Y and Yu J: Oxymatrine protects neonatal rat
against hypoxic-ischemic brain damage via PI3K/AKT/GSK3β pathway.
Life Sci. 254(116444)2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Liu L, Lu W, Ma Z and Li Z: Oxymatrine
attenuates bleomycin-induced pulmonary fibrosis in mice via the
inhibition of inducible nitric oxide synthase expression and the
TGF-β/Smad signaling pathway. Int J Mol Med. 29:815–822.
2012.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Morikawa M, Derynck R and Miyazono K:
TGF-β and the TGF-β family: Context-dependent roles in cell and
tissue physiology. Cold Spring Harb Perspect Biol.
8(a021873)2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Kim KK, Sheppard D and Chapman HA: TGF-β1
signaling and tissue fibrosis. Cold Spring Harb Perspect Biol.
10(34)2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhang C, Zhu X, Hua Y, Zhao Q, Wang K,
Zhen L, Wang G, Lü J, Luo A, Cho WC, et al: YY1 mediates
TGF-β1-induced EMT and pro-fibrogenesis in alveolar epithelial
cells. Respir Res. 20(249)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chen X, Sun R, Hu J, Mo Z, Yang Z, Liao D
and Zhong N: Attenuation of bleomycin-induced lung fibrosis by OMT
is associated with regulation of fibroblast proliferation and
collagen production in primary culture. Basic Clin Pharmacol
Toxicol. 103:278–286. 2008.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ruwanpura SM, Thomas BJ and Bardin PG:
Pirfenidone: Molecular mechanisms and potential clinical
applications in lung disease. Am J Respir Cell Mol Biol.
62:413–422. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Hosseini SA, Zahedipour F, Sathyapalan T,
Jamialahmadi T and Sahebkar A: Pulmonary fibrosis: Therapeutic and
mechanistic insights into the role of phytochemicals. Biofactors.
47:250–269. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Hu C, Wang Y, Fan Y, Li H, Wang C, Zhang
J, Zhang S, Han X and Wen C: Lipidomics revealed idiopathic
pulmonary fibrosis-induced hepatic lipid disorders corrected with
treatment of baicalin in a murine model. AAPS J. 17:711–722.
2015.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kumar RK: Idiopathic pulmonary fibrosis:
An epithelial/fibroblasticcross-talk disorder. Respir Res.
3(29)2002.
|
|
50
|
Snijder J, Peraza J, Padilla M, Capaccione
K and Salvatore MM: Pulmonary fibrosis: A disease of alveolar
collapse and collagen deposition. Expert Rev Respir Med.
13:615–619. 2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Guillot L, Nathan N, Tabary O, Thouvenin
G, Rouzic PL, Corvol H, Amselem S and Clement A: Alveolar
epithelial cells: Master regulators of lung homeostasis. Int J
Biochem Cell Biol. 45:2568–2573. 2013.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Serrano-Mollar A: Alveolar epithelial cell
injury as an etiopathogenic factor in pulmonary fibrosis. Arch
Bronconeumol. 48:2–6. 2012.PubMed/NCBI View Article : Google Scholar : (In Spanish).
|
|
53
|
Lu J, Wu L, Wang X, Zhu J, Du J and Shen
B: Detection of mitochondria membrane potential to study CLIC4
knockdown-induced HN4 cell apoptosis in vitro. J Vis Exp.
137(56137)2018.PubMed/NCBI View
Article : Google Scholar
|
|
54
|
Hill C, Jones MG, Davies DE and Wang Y:
Epithelial-mesenchymal transition contributes to pulmonary fibrosis
via aberrant epithelial/fibroblastic cross-talk. J Lung Health Dis.
3:31–35. 2019.PubMed/NCBI
|
|
55
|
Wang YC, Liu JS, Tang HK, Nie J, Zhu JX,
Wen LL and Guo QL: miR 221 targets HMGA2 to inhibit bleomycin
induced pulmonary fibrosis by regulating TGF β1/Smad3-induced EMT.
Int J Mol Med. 38:1208–1216. 2016.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Liu Y, Li Y, Xu Q, Yao W, Wu Q, Yuan J,
Yan W, Xu T, Ji X and Ni C: Long non-coding RNA-ATB promotes EMT
during silica-induced pulmonary fibrosis by competitively binding
miR-200c. Biochim Biophys Acta Mol Basis Dis. 1864:420–431.
2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Braun F, de Carné Trécesson S,
Bertin-Ciftci J and Juin P: Protect and serve: Bcl-2 proteins as
guardians and rulers of cancer cell survival. Cell Cycle.
12:2937–2947. 2013.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Willis S, Day CL, Hinds MG and Huang DC:
The Bcl-2-regulated apoptotic pathway. J Cell Sci. 15:4053–4056.
2003.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Kuwano K, Hagimoto N, Tanaka T, Kawasaki
M, Kunitake R, Miyazaki H, Kaneko Y, Matsuba T, Maeyama T and Hara
N: Expression of apoptosis-regulatory genes in epithelial cells in
pulmonary fibrosis in mice. J Pathol. 190:221–229. 2000.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Franke TF, Hornik CP, Segev L, Shostak GA
and Sugimoto C: PI3K/AKT and apoptosis: Size matters. Oncogene.
22:8983–8998. 2003.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z,
Li W, Hu J, Lu C and Liu Y: PI3K/AKT pathway as a key link
modulates the multidrug resistance of cancers. Cell Death Dis.
11(797)2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Sun Y, Zhang Y and Chi P: Pirfenidone
suppresses TGF-β1-induced human intestinal fibroblasts activities
by regulating proliferation and apoptosis via the inhibition of the
Smad and PI3K/AKT signaling pathway. Mol Med Rep. 18:3907–3913.
2018.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Liu MW, Su MX, Tang DY, Hao L, Xun XH and
Huang YQ: Ligustrazin increases lung cell autophagy and ameliorates
paraquat-induced pulmonary fibrosis by inhibiting PI3K/AKT/mTOR and
hedgehog signalling via increasing miR-193a expression. BMC Pulm
Med. 19(35)2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Moodley YP, Caterina P, Scaffidi AK, Misso
NL, Papadimitriou JM, McAnulty RJ, Laurent GJ, Thompson PJ and
Knight DA: Comparison of the morphological and biochemical changes
in normal human lung fibroblasts and fibroblasts derived from lungs
of patients with idiopathic pulmonary fibrosis during FasL-induced
apoptosis. J Pathol. 202:486–495. 2004.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Lu Y, Azad N, Wang L, Iyer AK, Castranova
V, Jiang BH and Rojanasakul Y: Phosphatidylinositol-3-kinase/AKT
regulates bleomycin-induced fibroblast proliferation and collagen
production. Am J Respir Cell Mol Biol. 42:432–441. 2010.PubMed/NCBI View Article : Google Scholar
|
